Receiving a cancer diagnosis is profoundly devastating, especially when it involves the brain. Rachel Guberman experienced this at 50 when she was diagnosed with Oligodendroglioma, the most common type of brain cancer. This cancer type typically grows slowly and is often deemed incurable. Although surgery might be considered, it frequently spreads, leaving chemotherapy and radiation as the main treatments. However, these therapies have their own limitations. That’s why this new brain cancer medication is so transformative.
The medicine, called Vorasidenib, has undergone trials and has shown promise in halting the growth of lower-grade brain tumors. Doctors are calling it a “game changer.” Nearly half of the patients in these trials have avoided chemotherapy and radiation years later. Discover more about this groundbreaking brain cancer drug and Rachel’s journey in the video below.
With nearly 25,000 people expected to be diagnosed with malignant brain and spinal cord tumors, it’s evident that medications like this can significantly change lives. The impact is already visible in trial participants, including Rachel.
Medications and treatments often take years to gain approval. That’s why it’s thrilling that, after extensive trials, Vorasidenib might receive FDA approval as soon as August 20 next month!
Life-Saving Brain Cancer Drug May Get FDA Approval Soon
“What’s exciting is this is a development that we haven’t seen in over 20 years,” says Katherine B. Peters, neuro-oncologist at Duke Cancer Center. “When we compared our patients who received Vorasidenib with those who received a placebo, the results were striking. Patients on Vorasidenib had a significantly improved prognosis, with progression-free survival extending to 27.7 months compared to just 11 months—a very large, statistically significant difference.”
